NASDAQ:INGN

Inogen Stock Forecast, Price & News

$43.97

-1.42 (-3.13 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$43.75

Now: $43.97▼

$45.90

50-Day Range

$35.07

MA: $42.02▼

$49.11

52-Week Range

$26.57

Now: $43.97▼

$55.55

Volume233,520 shs

Average Volume168,052 shs

Market Capitalization$972.53 million

P/E RatioN/A

Dividend YieldN/A

Beta1.05

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

MarketRank^™

Overall MarketRank^™

1.33 out of 5 stars

Medical Sector

525th out of 1,480 stocks

Surgical Appliances & Supplies Industry

16th out of 31 stocks

2.0 Analyst's Opinion

Consensus Rating
Inogen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $53.75, Inogen has a forecasted upside of 22.2% from its current price of $43.97.
Amount of Analyst Coverage
Inogen has only been the subject of 2 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Inogen has received 377 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Inogen has received 256 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Inogen has received 59.56% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote “Outperform” if you believe INGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Inogen does not currently pay a dividend.
Dividend Growth
Inogen does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $864,187.00 in company stock.
Percentage Held by Insiders
Only 4.83% of the stock of Inogen is held by insiders.
Percentage Held by Institutions
95.07% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Inogen are expected to decrease in the coming year, from ($0.31) to ($0.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inogen is -488.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inogen is -488.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inogen has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:INGN

Previous Symbol

CUSIPN/A

CIK1294133

Webwww.inogen.com

Phone805-562-0500

Employees1,020

Debt

Debt-to-Equity RatioN/A

Current Ratio5.84

Quick Ratio5.28

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$361.94 million

Price / Sales2.69

Cash Flow$1.63 per share

Price / Cash Flow26.94

Book Value$15.67 per share

Price / Book2.81

Profitability

EPS (Most Recent Fiscal Year)$1.07

Net Income$20.95 million

Net Margins-0.66%

Return on Equity0.21%

Return on Assets0.16%

Miscellaneous

Outstanding Shares22,118,000

Market Cap$972.53 million

Next Earnings Date2/23/2021 (Estimated)

OptionableOptionable

$43.97

-1.42 (-3.13 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.

Inogen (NASDAQ:INGN) Frequently Asked Questions

How has Inogen's stock been impacted by COVID-19 (Coronavirus)?

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INGN stock has increased by 8.3% and is now trading at $43.97.
View which stocks have been most impacted by COVID-19.

Is Inogen a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View analyst ratings for Inogen or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Inogen?

Wall Street analysts have given Inogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Inogen's next earnings date?

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Inogen.

How were Inogen's earnings last quarter?

Inogen, Inc. (NASDAQ:INGN) issued its quarterly earnings results on Wednesday, November, 4th. The medical technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.06. The medical technology company earned $74.30 million during the quarter, compared to analyst estimates of $76.06 million. Inogen had a negative net margin of 0.66% and a positive return on equity of 0.21%. The firm's revenue for the quarter was down 19.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.31 earnings per share.
View Inogen's earnings history.

What price target have analysts set for INGN?

5 analysts have issued 1 year price objectives for Inogen's stock. Their forecasts range from $35.00 to $75.00. On average, they anticipate Inogen's share price to reach $53.75 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Inogen or view Wall Street analyst' top-rated stocks.

Who are some of Inogen's key competitors?

Some companies that are related to Inogen include Avanos Medical (AVNS), Eargo (EAR), Establishment Labs (ESTA), Invacare (IVC), Lakeland Industries (LAKE), Sientra (SIEN), Histogenics (HSGX), United Health Products (UEEC), Milestone Scientific (MLSS), Surgalign (SRGA), Alpha Pro Tech (APT), CollPlant Biotechnologies (CLGN), Nutriband (NTRB), Conformis (CFMS) and Myomo (MYO).
View all of INGN's competitors.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Who are Inogen's key executives?

Inogen's management team includes the following people:

Mr. Scott Wilkinson, CEO, Pres & Director (Age 56, Pay $520.62k)
Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 40, Pay $325.88k)
Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Corp. Treasurer (Age 40, Pay $371.06k)
Mr. Byron Myers, Founder & Exec. VP of Marketing (Age 42, Pay $356.95k)
Mr. Bart Sanford, Exec. VP of Operations (Age 55, Pay $372.87k)
Mr. Matthew James Bacso C.F.A., CFA, Investor Relations & Corp. Devel. Mang.
Mr. Arron Retterer, Exec. VP of Sales
Mr. Matthew Pigeon, Investor Relations Officer

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Who are Inogen's major shareholders?

Inogen's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.06%) and 6 Meridian (0.02%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Heath Lukatch and Loren L Mcfarland.
View institutional ownership trends for Inogen.

Which major investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, and Brenton Taylor.
View insider buying and selling activity for Inogen or view top insider-selling stocks.

Which major investors are buying Inogen stock?

INGN stock was acquired by a variety of institutional investors in the last quarter, including 6 Meridian. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen or or view top insider-buying stocks.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $43.97.

How big of a company is Inogen?

Inogen has a market capitalization of $972.53 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

What is Inogen's official website?

The official website for Inogen is www.inogen.com.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here